The effectiveness and value of novel treatments for cystic fibrosis

Jeffrey A. Tice, Karen M. Kuntz, Kael Wherry, Matt Seidner, David M. Rind, Steven D. Pearson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)276-280
Number of pages5
JournalJournal of Managed Care and Specialty Pharmacy
Issue number2
StatePublished - Feb 2021

Bibliographical note

Funding Information:
Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER’s annual policy summit is supported by dues from Aetna, America’s Health Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/ Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare.


  • Adolescent
  • Aminophenols/economics
  • Aminopyridines/economics
  • Benzodioxoles/economics
  • Child
  • Chloride Channel Agonists/economics
  • Cost-Benefit Analysis
  • Cystic Fibrosis/drug therapy
  • Cystic Fibrosis Transmembrane Conductance Regulator/agonists
  • Drug Approval/economics
  • Drug Combinations
  • Drug Costs
  • Health Policy/economics
  • Humans
  • Indoles/economics
  • Models, Economic
  • Mutation
  • Pyrazoles/economics
  • Pyridines/economics
  • Quinolines/economics
  • Quinolones/economics
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

PubMed: MeSH publication types

  • Journal Article

Cite this